teriflunomide (BioDeep_00000758087)
代谢物信息卡片
teriflunomide
化学式: C12H9F3N2O2 (270.0616)
中文名称: 特立氟胺
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC(=C(C#N)C(=O)NC1=CC=C(C=C1)C(F)(F)F)O
InChI: InChI=1S/C12H9F3N2O2/c1-7(18)10(6-16)11(19)17-9-4-2-8(3-5-9)12(13,14)15/h2-5,18H,1H3,(H,17,19)/b10-7-
描述信息
An enamide obtained by formal condensation of the carboxy group of (2Z)-2-cyano-3-hydroxybut-2-enoic acid with the anilino group of 4-(trifluoromethyl)aniline. Used for the treatment of relapsing forms of multiple sclerosis and rheumatoid arthritis.
L - Antineoplastic and immunomodulating agents > L04 - Immunosuppressants > L04A - Immunosuppressants > L04AA - Selective immunosuppressants
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents
D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents
D002491 - Central Nervous System Agents > D000700 - Analgesics
D000893 - Anti-Inflammatory Agents
D018501 - Antirheumatic Agents
C471 - Enzyme Inhibitor
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
同义名列表
1 个代谢物同义名
数据库引用编号
7 个数据库交叉引用编号
- ChEBI: CHEBI:68540
- KEGGdrug: D10172
- PubChem: 54684141
- DrugBank: DB08880
- CAS: 163451-81-8
- CAS: 108605-62-5
- MetaboLights: MTBLC68540
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Xiaoyue Ji, Junhong Chen, Chaoying You, Jing Sun, Xiulong Xu. Leflunomide alleviates obesity via activation of the TAK1-AMPK pathway and induction of lipophagy.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
2023 11; 37(11):e23227. doi:
10.1096/fj.202301162r. [PMID: 37792678] - Heba Abd-El-Azim, Haidy Abbas, Nesrine S El Sayed, Ahmed M Fayez, Mariam Zewail. Non-invasive management of rheumatoid arthritis using hollow microneedles as a tool for transdermal delivery of teriflunomide loaded solid lipid nanoparticles.
International journal of pharmaceutics.
2023 Aug; 644(?):123334. doi:
10.1016/j.ijpharm.2023.123334. [PMID: 37604364] - Chungen Li, Yue Zhou, Jing Xu, Xia Zhou, Zongkai Huang, Ting Zeng, Xiaowei Yang, Lei Tao, Kun Gou, Xi Zhong, Qiang Chen, Youfu Luo, Yinglan Zhao. A novel series of teriflunomide derivatives as orally active inhibitors of human dihydroorotate dehydrogenase for the treatment of colorectal carcinoma.
European journal of medicinal chemistry.
2022 Aug; 238(?):114489. doi:
10.1016/j.ejmech.2022.114489. [PMID: 35640328] - Mariam Zewail, Nehal M El-Deeb, Mohamed R Mousa, Haidy Abbas. Hyaluronic acid coated teriflunomide (A771726) loaded lipid carriers for the oral management of rheumatoid arthritis.
International journal of pharmaceutics.
2022 Jul; 623(?):121939. doi:
10.1016/j.ijpharm.2022.121939. [PMID: 35724825] - L Lorefice, S Pilotto, G Fenu, P Cimino, D Firinu, J Frau, F Murgia, G Coghe, E Cocco. Evolution of teriflunomide use in multiple sclerosis: A real-world experience.
Journal of the neurological sciences.
2022 Jul; 438(?):120292. doi:
10.1016/j.jns.2022.120292. [PMID: 35605316] - Ofir Zmira, Shany Guly Gofrit, Shay Anat Aharoni, Ronen Weiss, Efrat Shavit-Stein, Joab Chapman. Teriflunomide normalizes anti-anxiety effect in anti-ANXA2 APS mice model teriflunomide in anti-ANXA2 mice model.
Lupus.
2022 Jun; 31(7):855-863. doi:
10.1177/09612033221095150. [PMID: 35575144] - Nicte S Fajardo-Robledo, Heriberto Jacobo-Cuevas, Edsaul E Perez-Guerrero, Esther G Corona-Sanchez, A Miriam Saldaña-Cruz, Elba M Romero-Tejeda, N Alejandra Rodriguez-Jimenez, Sylvia E Totsuka-Sutto, Rocio I Lopez-Roa, Juan M Ponce-Guarneros, M Fabiola Alcaraz-Lopez, Sergio Cerpa-Cruz, J Francisco Muñoz-Valle, E German Cardona-Muñoz, Laura Gonzalez-Lopez, Jorge I Gamez-Nava. Therapeutic response to leflunomide in combo therapy and monotherapy is associated to serum teriflunomide (A77 1726) levels.
Scientific reports.
2022 02; 12(1):1877. doi:
10.1038/s41598-022-05644-7. [PMID: 35115601] - Ran Zhou, Hongliang Li, Huan Yang, Fei Jiang, Haobing Cai, Jing Li, Si Chen, Liangjuan Fang, Jun Yin, Qiuming Zeng. Serological markers exploration and real-world effectiveness and safety of teriflunomide in south Chinese patients with multiple sclerosis.
Multiple sclerosis and related disorders.
2022 Feb; 58(?):103446. doi:
10.1016/j.msard.2021.103446. [PMID: 34929454] - Joseph B Guarnaccia, Ann Cabot, Lore L Garten, Salvatore Napoli, Mayer J Hasbani. Teriflunomide levels in women whose male sexual partner is on teriflunomide for relapsing multiple sclerosis.
Multiple sclerosis and related disorders.
2022 Jan; 57(?):103347. doi:
10.1016/j.msard.2021.103347. [PMID: 35158456] - Chungen Li, Xiaowei Yang, Yuan Luo, Huan Liu, Xi Zhong, Xia Zhou, Ting Zeng, Lei Tao, Yue Zhou, Kun Gou, Xinyu Yang, Xiaocong Liu, Qiang Chen, Yinglan Zhao, Youfu Luo. Design, Synthesis, and Biological Evaluation of a Novel Series of Teriflunomide Derivatives as Potent Human Dihydroorotate Dehydrogenase Inhibitors for Malignancy Treatment.
Journal of medicinal chemistry.
2021 12; 64(24):18175-18192. doi:
10.1021/acs.jmedchem.1c01711. [PMID: 34905371] - Paola Mian, W Tobias van Haaften, Marijke Assink, Regine J H M van Drie-Pierik. Acute teriflunomide overdose with relatively mild symptoms: A case report.
Journal of clinical pharmacy and therapeutics.
2021 Dec; 46(6):1784-1786. doi:
10.1111/jcpt.13360. [PMID: 33421160] - Bérenger Largeau, Frédéric Béra, Jacques Vannier, Annie-Pierre Jonville-Béra. Teriflunomide-associated urolithiasis: a new adverse reaction explained by its uricosuric effect.
Fundamental & clinical pharmacology.
2021 Oct; 35(5):930-932. doi:
10.1111/fcp.12647. [PMID: 33458875] - Bethany A O'Hara, Gretchen V Gee, Sheila A Haley, Jenna Morris-Love, Charlotte Nyblade, Chris Nieves, Barbara A Hanson, Xin Dang, Timothy J Turner, Jeffrey M Chavin, Alex Lublin, Igor J Koralnik, Walter J Atwood. Teriflunomide Inhibits JCPyV Infection and Spread in Glial Cells and Choroid Plexus Epithelial Cells.
International journal of molecular sciences.
2021 Sep; 22(18):. doi:
10.3390/ijms22189809. [PMID: 34575975] - Hardeep Kaur, Phulen Sarma, Anusuya Bhattacharyya, Saurabh Sharma, Neeraj Chhimpa, Manisha Prajapat, Ajay Prakash, Subodh Kumar, Ashutosh Singh, Rahul Singh, Pramod Avti, Prasad Thota, Bikash Medhi. Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review.
European journal of pharmacology.
2021 Sep; 906(?):174233. doi:
10.1016/j.ejphar.2021.174233. [PMID: 34111397] - Geraldine Luetic, María L Menichini, Marcos Burgos, Ricardo Alonso, Edgar Carnero Contentti, Adriana Carrá, Norma Deri, Judith Steinberg, Juan I Rojas. COVID-19 in Argentine teriflunomide-treated multiple sclerosis patients: First national case series.
Multiple sclerosis and related disorders.
2021 Aug; 53(?):103049. doi:
10.1016/j.msard.2021.103049. [PMID: 34130197] - Vuslat Yilmaz, Canan Ulusoy, Sabastian Hajtovic, Recai Turkoglu, Murat Kurtuncu, John Tzartos, Konstantinos Lazaridis, Erdem Tuzun. Effects of Teriflunomide on B Cell Subsets in MuSK-Induced Experimental Autoimmune Myasthenia Gravis and Multiple Sclerosis.
Immunological investigations.
2021 Aug; 50(6):671-684. doi:
10.1080/08820139.2020.1785491. [PMID: 32597289] - Michael D Wiese, Ashley M Hopkins, Catherine King, Mihir D Wechalekar, Anita Lee, Llewellyn Spargo, Robert Metcalf, Leah McWilliams, Catherine Hill, Leslie G Cleland, Susanna M Proudman. Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis.
Arthritis care & research.
2021 07; 73(7):983-989. doi:
10.1002/acr.24236. [PMID: 32339392] - Vittorio Mantero, Damiano Baroncini, Roberto Balgera, Clara Guaschino, Paola Basilico, Pietro Annovazzi, Mauro Zaffaroni, Andrea Salmaggi, Christian Cordano. Mild COVID-19 infection in a group of teriflunomide-treated patients with multiple sclerosis.
Journal of neurology.
2021 Jun; 268(6):2029-2030. doi:
10.1007/s00415-020-10196-9. [PMID: 32865629] - Mehmet Fatih Yetkin, Nur Aleyna Yetkin, Merve Akcakoyunlu, Meral Mirza. Transient monocular visual impairment as an initial symptom of COVID-19 infection in an individual with multiple sclerosis receiving teriflunomide.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology.
2021 May; 42(5):1661-1664. doi:
10.1007/s10072-021-05097-2. [PMID: 33534122] - Anthony T Reder, Diego Centonze, Maria L Naylor, Anjali Nagpal, Rajani Rajbhandari, Arman Altincatal, Michelle Kim, Aaron Berdofe, Maha Radhakrishnan, Eunice Jung, Alfred W Sandrock, Karen Smirnakis, Catrinel Popescu, Carl de Moor. COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies.
CNS drugs.
2021 03; 35(3):317-330. doi:
10.1007/s40263-021-00804-1. [PMID: 33743151] - Yao Li, Li Yi, Sipeng Cheng, Yongshan Wang, Jiongjiong Wang, Jing Sun, Quan Zhang, Xiulong Xu. Inhibition of canine distemper virus replication by blocking pyrimidine nucleotide synthesis with A77 1726, the active metabolite of the anti-inflammatory drug leflunomide.
The Journal of general virology.
2021 03; 102(3):. doi:
10.1099/jgv.0.001534. [PMID: 33416466] - Fioravante Capone, Francesco Motolese, Tiziano Luce, Mariagrazia Rossi, Alessandro Magliozzi, Vincenzo Di Lazzaro. COVID-19 in teriflunomide-treated patients with multiple sclerosis: A case report and literature review.
Multiple sclerosis and related disorders.
2021 Feb; 48(?):102734. doi:
10.1016/j.msard.2020.102734. [PMID: 33429305] - Michael Kurz, Dirk Gretzke, Rolf Hörlein, Sandrine Turpault, Jens Atzrodt, Volker Derdau. Carbon-13 synthesis and NMR spectroscopic geometric isomer evaluation to support the filing of teriflunomide.
Journal of labelled compounds & radiopharmaceuticals.
2021 02; 64(2):82-88. doi:
10.1002/jlcr.3876. [PMID: 32840004] - Dnyandev Gadhave, Nishant Rasal, Rahul Sonawane, Mahendran Sekar, Chandrakant Kokare. Nose-to-brain delivery of teriflunomide-loaded lipid-based carbopol-gellan gum nanogel for glioma: Pharmacological and in vitro cytotoxicity studies.
International journal of biological macromolecules.
2021 Jan; 167(?):906-920. doi:
10.1016/j.ijbiomac.2020.11.047. [PMID: 33186648] - Nora Möhn, Firas Saker, Viktoria Bonda, Gesine Respondek, Marcus Bachmann, Matthias Stoll, Mike P Wattjes, Martin Stangel, Thomas Skripuletz. Mild COVID-19 symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to multiple sclerosis relapse.
Journal of neurology.
2020 Oct; 267(10):2803-2805. doi:
10.1007/s00415-020-09921-1. [PMID: 32494855] - Amir Hadi Maghzi, Maria K Houtchens, Paolo Preziosa, Carolina Ionete, Biljana D Beretich, James M Stankiewicz, Shahamat Tauhid, Ann Cabot, Idanis Berriosmorales, Tamara H W Schwartz, Jacob A Sloane, Mark S Freedman, Massimo Filippi, Howard L Weiner, Rohit Bakshi. COVID-19 in teriflunomide-treated patients with multiple sclerosis.
Journal of neurology.
2020 Oct; 267(10):2790-2796. doi:
10.1007/s00415-020-09944-8. [PMID: 32494856] - Rui Xiong, Leike Zhang, Shiliang Li, Yuan Sun, Minyi Ding, Yong Wang, Yongliang Zhao, Yan Wu, Weijuan Shang, Xiaming Jiang, Jiwei Shan, Zihao Shen, Yi Tong, Liuxin Xu, Yu Chen, Yingle Liu, Gang Zou, Dimitri Lavillete, Zhenjiang Zhao, Rui Wang, Lili Zhu, Gengfu Xiao, Ke Lan, Honglin Li, Ke Xu. Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.
Protein & cell.
2020 10; 11(10):723-739. doi:
10.1007/s13238-020-00768-w. [PMID: 32754890] - Ana R Coelho, Paulo J Oliveira. Dihydroorotate dehydrogenase inhibitors in SARS-CoV-2 infection.
European journal of clinical investigation.
2020 Oct; 50(10):e13366. doi:
10.1111/eci.13366. [PMID: 32735689] - Sara Salama, Samar Farouk Ahmed, Ismail Ibrahim Ismail, Raed Alroughani. Impact of coronavirus disease (COVID-19) pandemic on multiple sclerosis care.
Clinical neurology and neurosurgery.
2020 10; 197(?):106203. doi:
10.1016/j.clineuro.2020.106203. [PMID: 32919242] - Luca Bollo, Tommaso Guerra, Davide Fiore Bavaro, Laura Monno, Annalisa Saracino, Gioacchino Angarano, Damiano Paolicelli, Maria Trojano, Pietro Iaffaldano. Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide.
Journal of the neurological sciences.
2020 09; 416(?):117011. doi:
10.1016/j.jns.2020.117011. [PMID: 32650143] - James D Bowen, Justine Brink, Ted R Brown, Elisabeth B Lucassen, Kyle Smoot, Annette Wundes, Pavle Repovic. COVID-19 in MS: Initial observations from the Pacific Northwest.
Neurology(R) neuroimmunology & neuroinflammation.
2020 09; 7(5):. doi:
10.1212/nxi.0000000000000783. [PMID: 32457226] - Stephen L Hauser, Amit Bar-Or, Jeffrey A Cohen, Giancarlo Comi, Jorge Correale, Patricia K Coyle, Anne H Cross, Jerome de Seze, David Leppert, Xavier Montalban, Krzysztof Selmaj, Heinz Wiendl, Cecile Kerloeguen, Roman Willi, Bingbing Li, Algirdas Kakarieka, Davorka Tomic, Alexandra Goodyear, Ratnakar Pingili, Dieter A Häring, Krishnan Ramanathan, Martin Merschhemke, Ludwig Kappos. Ofatumumab versus Teriflunomide in Multiple Sclerosis.
The New England journal of medicine.
2020 08; 383(6):546-557. doi:
10.1056/nejmoa1917246. [PMID: 32757523] - Jiongjiong Wang, Jing Sun, Jiao Hu, Chengming Wang, Richard A Prinz, Daxin Peng, Xiufan Liu, Xiulong Xu. A77 1726, the active metabolite of the anti-rheumatoid arthritis drug leflunomide, inhibits influenza A virus replication in vitro and in vivo by inhibiting the activity of Janus kinases.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
2020 08; 34(8):10132-10145. doi:
10.1096/fj.201902793rr. [PMID: 32598086] - Farinaz Safavi, Bardia Nourbakhsh, Amir Reza Azimi. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
Multiple sclerosis and related disorders.
2020 Aug; 43(?):102195. doi:
10.1016/j.msard.2020.102195. [PMID: 32460086] - David Baker, Sandra Amor, Angray S Kang, Klaus Schmierer, Gavin Giovannoni. The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.
Multiple sclerosis and related disorders.
2020 Aug; 43(?):102174. doi:
10.1016/j.msard.2020.102174. [PMID: 32464584] - Mohammad-Reza Rouini, Maryam Dibaei, Elham Ghasemian. Pharmacokinetics and Bioequivalence Studies of Teriflunomide in Healthy Iranian Volunteers.
Clinical pharmacology in drug development.
2020 04; 9(3):341-345. doi:
10.1002/cpdd.725. [PMID: 31379101] - Xiao-Ying Liao, Qiang-Qiang Deng, Li Han, Zhi-Tao Wu, Zhao-Liang Peng, Yuan Xie, Guang-Ji Wang, Ji-Ye Aa, Guo-Yu Pan. Leflunomide increased the renal exposure of acyclovir by inhibiting OAT1/3 and MRP2.
Acta pharmacologica Sinica.
2020 Jan; 41(1):129-137. doi:
10.1038/s41401-019-0283-z. [PMID: 31341258] - Robert Zivadinov, Murali Ramanathan, Jesper Hagemeier, Niels Bergsland, Deepa P Ramasamy, Jacqueline Durfee, Channa Kolb, Bianca Weinstock-Guttman. Teriflunomide's effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis.
Multiple sclerosis and related disorders.
2019 Nov; 36(?):101388. doi:
10.1016/j.msard.2019.101388. [PMID: 31525628] - Xueting Yao, Yiwen Wu, Ji Jiang, Pei Hu, Dongyang Liu, Xia Chen. Safety, Pharmacokinetics, and Pharmacogenetics of Single-Dose Teriflunomide Sodium and Leflunomide in Healthy Chinese Subjects.
Clinical drug investigation.
2019 Jul; 39(7):643-651. doi:
10.1007/s40261-019-00786-5. [PMID: 31016613] - Dnyandev G Gadhave, Chandrakant R Kokare. Nanostructured lipid carriers engineered for intranasal delivery of teriflunomide in multiple sclerosis: optimization and in vivo studies.
Drug development and industrial pharmacy.
2019 May; 45(5):839-851. doi:
10.1080/03639045.2019.1576724. [PMID: 30702966] - Xueting Yao, Yang Liu, Ling Song, Ji Jiang, Fei Xiao, Dongyang Liu, Pei Hu. Development of a simple HPLC-MS/MS method to simultaneously determine teriflunomide and its metabolite in human plasma and urine: Application to clinical pharmacokinetic study of teriflunomide sodium and leflunomide.
Biomedical chromatography : BMC.
2019 Mar; 33(3):e4420. doi:
10.1002/bmc.4420. [PMID: 30362147] - Yaru Cao, Huifang Gao, Hongguang Xia, Xiangyu Zhu, Biao Li, Xuya Zhou, Yong Jin. Development and Evaluation of a Water-in-oil Microemulsion Formulation for the Transdermal Drug Delivery of Teriflunomide (A771726).
Chemical & pharmaceutical bulletin.
2019; 67(8):786-794. doi:
10.1248/cpb.c18-00930. [PMID: 31366828] - Geoffrey S Rule, Alan L Rockwood, Kamisha L Johnson-Davis. LC-MS/MS Method for the Quantification of the Leflunomide Metabolite, Teriflunomide, in Human Serum/Plasma.
Methods in molecular biology (Clifton, N.J.).
2019; 1872(?):75-83. doi:
10.1007/978-1-4939-8823-5_8. [PMID: 30350281] - Zsolt Sáfár, Márton Jani, Ildikó Makai, Zsolt Fekete, Annamária Bui, Éva Molnár, Petra Pádár, Jennifer R Pratt, Emese Kis, Erzsébet Beéry, Péter Krajcsi. Correlation Analysis of Potential Breast Cancer Resistance Protein Probes in Different Monolayer Systems.
Journal of pharmaceutical sciences.
2018 11; 107(11):2742-2747. doi:
10.1016/j.xphs.2018.07.014. [PMID: 30055222] - Junhong Chen, Jing Sun, Michelle E Doscas, Jin Ye, Ashley J Williamson, Yanchun Li, Yi Li, Richard A Prinz, Xiulong Xu. Control of hyperglycemia in male mice by leflunomide: mechanisms of action.
The Journal of endocrinology.
2018 04; 237(1):43-58. doi:
10.1530/joe-17-0536. [PMID: 29496905] - Derrick Robertson, Crystal Dixon, Angela Aungst, Bradlee McCoy, Natalie Moreo, Lise Casady, Janice Maldonado. Tolerability and efficacy of colestipol hydrochloride for accelerated elimination of teriflunomide.
Expert review of clinical pharmacology.
2017 Dec; 10(12):1403-1407. doi:
10.1080/17512433.2017.1395280. [PMID: 29064296] - Su-Jin Moon, Eun-Kyung Kim, Joo Yeon Jhun, Hee Jin Lee, Weon Sun Lee, Sang-Hi Park, Mi-La Cho, Jun-Ki Min. The active metabolite of leflunomide, A77 1726, attenuates inflammatory arthritis in mice with spontaneous arthritis via induction of heme oxygenase-1.
Journal of translational medicine.
2017 02; 15(1):31. doi:
10.1186/s12967-017-1131-x. [PMID: 28193225] - Ashley M Hopkins, Mahin Moghaddami, David J R Foster, Susanna M Proudman, Richard N Upton, Michael D Wiese. Intracellular CD3+ T Lymphocyte Teriflunomide Concentration Is Poorly Correlated with and Has Greater Variability Than Unbound Plasma Teriflunomide Concentration.
Drug metabolism and disposition: the biological fate of chemicals.
2017 01; 45(1):8-16. doi:
10.1124/dmd.116.071985. [PMID: 27742727] - A Suneetha, Rajeswari K Raja. Comparison of LC-UV and LC-MS methods for simultaneous determination of teriflunomide, dimethyl fumarate and fampridine in human plasma: application to rat pharmacokinetic study.
Biomedical chromatography : BMC.
2016 Sep; 30(9):1371-7. doi:
10.1002/bmc.3694. [PMID: 26849839] - Aziz Filali-Ansary, Catherine Lunven, Sandrine Turpault, Yann-Joel Beyer, Amy OʼBrien, Astrid Delfolie, Neli Boyanova, Ger-Jan Sanderink, Francesca Baldinetti. Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide.
Therapeutic drug monitoring.
2016 08; 38(4):471-82. doi:
10.1097/ftd.0000000000000302. [PMID: 27015245] - Lei-lei Ma, Zhi-tao Wu, Le Wang, Xue-feng Zhang, Jing Wang, Chen Chen, Xuan Ni, Yun-fei Lin, Yi-yi Cao, Yang Luan, Guo-yu Pan. Inhibition of hepatic cytochrome P450 enzymes and sodium/bile acid cotransporter exacerbates leflunomide-induced hepatotoxicity.
Acta pharmacologica Sinica.
2016 Mar; 37(3):415-24. doi:
10.1038/aps.2015.157. [PMID: 26806301] - Joonho Bae, Jin Woo Park. Topical delivery of leflunomide for rheumatoid arthritis treatment: evaluation of local tissue deposition of teriflunomide and its anti-inflammatory effects in an arthritis rat model.
Drug development and industrial pharmacy.
2016; 42(2):254-62. doi:
10.3109/03639045.2015.1044906. [PMID: 26006334] - Geoffrey S Rule, Alan L Rockwood, Kamisha L Johnson-Davis. Quantitation of Teriflunomide in Human Serum/Plasma Across a 40,000-Fold Concentration Range by LC/MS/MS.
Methods in molecular biology (Clifton, N.J.).
2016; 1383(?):195-203. doi:
10.1007/978-1-4939-3252-8_21. [PMID: 26660188] - Lei Jiang, Huaixiu Wen, Yun Shao, Ruitao Yu, Zenggen Liu, Shuo Wang, Qilan Wang, Xiaohui Zhao, Peng Zhang, Yanduo Tao, Lijuan Mei. Novel Diketopiperazine Dihydroorotate Dehydrogenase Inhibitors Purified from Traditional Tibetan Animal Medicine Osteon Myospalacem Baileyi.
Chemical biology & drug design.
2015 Oct; 86(4):626-36. doi:
10.1111/cbdd.12530. [PMID: 25626527] - Aaron E Miller. Teriflunomide: a once-daily oral medication for the treatment of relapsing forms of multiple sclerosis.
Clinical therapeutics.
2015 Oct; 37(10):2366-80. doi:
10.1016/j.clinthera.2015.08.003. [PMID: 26365096] - Geoffrey S Rule, Alan L Rockwood, Kamisha L Johnson-Davis. LC-MS/MS Method for Determination of Teriflunomide, Over a 40,000-Fold Dynamic Range Using Overlapping Calibrators.
Therapeutic drug monitoring.
2015 Aug; 37(4):472-8. doi:
10.1097/ftd.0000000000000166. [PMID: 25525756] - Guilin Qiao, Lifen Yang, Zhenping Li, James W Williams, Jian Zhang. A77 1726, the active metabolite of leflunomide, attenuates lupus nephritis by promoting the development of regulatory T cells and inhibiting IL-17-producing double negative T cells.
Clinical immunology (Orlando, Fla.).
2015 Apr; 157(2):166-74. doi:
10.1016/j.clim.2015.01.006. [PMID: 25638413] - Guang Fu Dong, Xiao Zhang, De Ning He, Ling Li, Guang Feng Zhang. Effect of Leflunomide on the Abnormal Expression of Lipid Rafts and F-Actin in B Lymphocytes from Patients with Systemic Lupus Erythematosus.
Journal of immunology research.
2015; 2015(?):832916. doi:
10.1155/2015/832916. [PMID: 26090500] - Y-J Lim, E-J Shim, H-S Kim, M Oh, J-H Shon, J-G Shin, B-S Moon, G-S Song, E-Y Kim. Pharmacokinetics and bioequivalence evaluation of leflunomide tablets in Korean healthy volunteers.
Drug research.
2013 Dec; 63(12):633-8. doi:
10.1055/s-0033-1349889. [PMID: 23884659] - Raoul Bergner, Lena Peters, Verena Schmitt, Christian Löffler. Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study.
Clinical rheumatology.
2013 Feb; 32(2):267-70. doi:
10.1007/s10067-012-2122-1. [PMID: 23179005] - C Balagué, M Pont, N Prats, N Godessart. Profiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant-induced arthritis model: a translational study.
British journal of pharmacology.
2012 Jun; 166(4):1320-32. doi:
10.1111/j.1476-5381.2012.01836.x. [PMID: 22229697] - Jill C Krisl, David J Taber, Nicole Pilch, Kenneth Chavin, Charles Bratton, Beje Thomas, John McGillicuddy, Prabhakar Baliga. Leflunomide efficacy and pharmacodynamics for the treatment of BK viral infection.
Clinical journal of the American Society of Nephrology : CJASN.
2012 Jun; 7(6):1003-9. doi:
10.2215/cjn.12531211. [PMID: 22461534] - M L Mehl, L Tell, A E Kyles, Y-J Chen, A Craigmill, C R Gregory. Pharmacokinetics and pharmacodynamics of A77 1726 and leflunomide in domestic cats.
Journal of veterinary pharmacology and therapeutics.
2012 Apr; 35(2):139-46. doi:
10.1111/j.1365-2885.2011.01306.x. [PMID: 21615755] - S Agarwal, A Das, D Ghosh, A K Sarkar, T K Chattaraj, T K Pal. Comparative bioequivalence study of leflunomide tablets in Indian healthy volunteers.
Arzneimittel-Forschung.
2012 Mar; 62(3):145-8. doi:
10.1055/s-0031-1298024. [PMID: 22278631] - Isabelle Hubeek, Alferso C Abrahams, Michiel de Bruin, Hans Kemperman. Falsely decreased ionized calcium results due to analytical interference by teriflunomide, the active metabolite of leflunomide (Arava®).
Clinical chemistry and laboratory medicine.
2012 Feb; 50(4):755-6. doi:
10.1515/cclm-2011-0781. [PMID: 22505564] - Erin E Olsan, Sambuddho Mukherjee, Beatrix Wulkersdorfer, Jonathan M Shillingford, Adrian J Giovannone, Gueorgui Todorov, Xuewen Song, York Pei, Thomas Weimbs. Signal transducer and activator of transcription-6 (STAT6) inhibition suppresses renal cyst growth in polycystic kidney disease.
Proceedings of the National Academy of Sciences of the United States of America.
2011 Nov; 108(44):18067-72. doi:
10.1073/pnas.1111966108. [PMID: 22025716] - Halima Rakhila, Tomas Rozek, Ashley Hopkins, Susanna Proudman, Les Cleland, Michael James, Michael Wiese. Quantitation of total and free teriflunomide (A77 1726) in human plasma by LC-MS/MS.
Journal of pharmaceutical and biomedical analysis.
2011 May; 55(2):325-31. doi:
10.1016/j.jpba.2011.01.034. [PMID: 21349677] - Kyoung-Ah Kim, Hyun-Jin Joo, Ji-Young Park. Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level.
European journal of clinical pharmacology.
2011 Feb; 67(2):129-34. doi:
10.1007/s00228-010-0916-0. [PMID: 20972558] - Jignesh M Parekh, Rajendrasinh N Vaghela, Dipen K Sutariya, Mallika Sanyal, Manish Yadav, Pranav S Shrivastav. Chromatographic separation and sensitive determination of teriflunomide, an active metabolite of leflunomide in human plasma by liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2010 Aug; 878(24):2217-25. doi:
10.1016/j.jchromb.2010.06.028. [PMID: 20643586] - Numsen Hail, Ping Chen, Jadwiga J Kepa, Lane R Bushman, Colin Shearn. Dihydroorotate dehydrogenase is required for N-(4-hydroxyphenyl)retinamide-induced reactive oxygen species production and apoptosis.
Free radical biology & medicine.
2010 Jul; 49(1):109-16. doi:
10.1016/j.freeradbiomed.2010.04.006. [PMID: 20399851] - Kimia Sobhani, Danette A Garrett, Dong-Pei Liu, Petrie M Rainey. A rapid and simple high-performance liquid chromatography assay for the leflunomide metabolite, teriflunomide (A77 1726), in renal transplant recipients.
American journal of clinical pathology.
2010 Mar; 133(3):454-7. doi:
10.1309/ajcpr23yaoyfsztx. [PMID: 20154284] - Eva Bernhoff, Garth D Tylden, Lars J Kjerpeseth, Tore J Gutteberg, Hans H Hirsch, Christine H Rinaldo. Leflunomide inhibition of BK virus replication in renal tubular epithelial cells.
Journal of virology.
2010 Feb; 84(4):2150-6. doi:
10.1128/jvi.01737-09. [PMID: 19955306] - Petra Bohanec Grabar, Iztok Grabnar, Blaz Rozman, Dusan Logar, Matija Tomsic, Dasa Suput, Tina Trdan, Lucija Peterlin Masic, Ales Mrhar, Vita Dolzan. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis.
Drug metabolism and disposition: the biological fate of chemicals.
2009 Oct; 37(10):2061-8. doi:
10.1124/dmd.109.027482. [PMID: 19581389] - Takeo Sato, Shigeko Inokuma, Akira Sagawa, Takemasa Matsuda, Tamiko Takemura, Takeshi Otsuka, Yukihiko Saeki, Tsutomu Takeuchi, Tetsuji Sawada. Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis.
Rheumatology (Oxford, England).
2009 Oct; 48(10):1265-8. doi:
10.1093/rheumatology/kep227. [PMID: 19651883] - Jae Youl Cho. Non-specific anti-proliferative effect of FTY720, a derivative of fungal metabolite from Iscaria sinclarii.
Archives of pharmacal research.
2008 Feb; 31(2):160-6. doi:
10.1007/s12272-001-1135-0. [PMID: 18365684] - Courtney R Williams, Jane E Sykes, Margo Mehl, Jennifer S MacLeod, LeAnn L Lindsay, Amy M Poland, Yi-Je Chen, Andrew E Kyles, W James Waldman, Clare R Gregory. In vitro effects of the active metabolite of leflunomide, A77 1726, on feline herpesvirus-1.
American journal of veterinary research.
2007 Sep; 68(9):1010-5. doi:
10.2460/ajvr.68.9.1010. [PMID: 17764417] - Michelle A Josephson, Daniel Gillen, Basit Javaid, Pradeep Kadambi, Shane Meehan, Preston Foster, Robert Harland, Richard J Thistlethwaite, Marc Garfinkel, Walter Atwood, Joslynn Jordan, Molly Sadhu, Michael J Millis, James Williams. Treatment of renal allograft polyoma BK virus infection with leflunomide.
Transplantation.
2006 Mar; 81(5):704-10. doi:
10.1097/01.tp.0000181149.76113.50. [PMID: 16534472] - Vivien Chan, Bruce G Charles, Susan E Tett. Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis.
British journal of clinical pharmacology.
2005 Sep; 60(3):257-64. doi:
10.1111/j.1365-2125.2005.02415.x. [PMID: 16120064] - K Migita, T Miyashita, Y Maeda, M Nakamura, H Yatsuhashi, H Ishibashi, K Eguchi. An active metabolite of leflunomide, A77 1726, inhibits the production of serum amyloid A protein in human hepatocytes.
Rheumatology (Oxford, England).
2005 Apr; 44(4):443-8. doi:
10.1093/rheumatology/keh462. [PMID: 15695308] - E N van Roon, T L T A Jansen, M A F J van de Laar, M Janssen, J P Yska, R Keuper, P M Houtman, J R B J Brouwers. Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis.
Annals of the rheumatic diseases.
2005 Apr; 64(4):569-74. doi:
10.1136/ard.2004.025205. [PMID: 15345501] - James W Williams, Basit Javaid, Predeep V Kadambi, Daniel Gillen, Robert Harland, J Richard Thistlewaite, Marc Garfinkel, Preston Foster, Walter Atwood, J Michael Millis, Shane M Meehan, Michelle A Josephson. Leflunomide for polyomavirus type BK nephropathy.
The New England journal of medicine.
2005 Mar; 352(11):1157-8. doi:
10.1056/nejm200503173521125. [PMID: 15784677] - E N van Roon, J P Yska, J Raemaekers, T L Th A Jansen, M van Wanrooy, J R B J Brouwers. A rapid and simple determination of A77 1726 in human serum by high-performance liquid chromatography and its application for optimization of leflunomide therapy.
Journal of pharmaceutical and biomedical analysis.
2004 Sep; 36(1):17-22. doi:
10.1016/j.jpba.2004.05.019. [PMID: 15351043] - M C Kraan, T J M Smeets, M J van Loon, F C Breedveld, B A C Dijkmans, P P Tak. Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis.
Annals of the rheumatic diseases.
2004 Sep; 63(9):1056-61. doi:
10.1136/ard.2003.014738. [PMID: 15115713] - Vivien Chan, Bruce G Charles, Susan E Tett. Rapid determination of the active leflunomide metabolite A77 1726 in human plasma by high-performance liquid chromatography.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2004 Apr; 803(2):331-5. doi:
10.1016/j.jchromb.2004.01.016. [PMID: 15063344] - Amit S Kalgutkar, Hang T Nguyen, Alfin D N Vaz, Anke Doan, Deepak K Dalvie, Dale G McLeod, John C Murray. In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active alpha-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes.
Drug metabolism and disposition: the biological fate of chemicals.
2003 Oct; 31(10):1240-50. doi:
10.1124/dmd.31.10.1240. [PMID: 12975333] - Andreas Schmidt, Bianca Schwind, Martin Gillich, Kay Brune, Burkhard Hinz. Simultaneous determination of leflunomide and its active metabolite, A77 1726, in human plasma by high-performance liquid chromatography.
Biomedical chromatography : BMC.
2003 Jun; 17(4):276-81. doi:
10.1002/bmc.244. [PMID: 12833393] - Jun Li, Hong-Wei Yao, Yong Jin, Yun-Fang Zhang, Chang-Yu Li, Yuan-Hai Li, Shu-Yun Xu. Pharmacokinetics of leflunomide in Chinese healthy volunteers.
Acta pharmacologica Sinica.
2002 Jun; 23(6):551-5. doi:
NULL. [PMID: 12060531] - L C Hamilton, I Vojnovic, T D Warner. A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner.
British journal of pharmacology.
1999 Aug; 127(7):1589-96. doi:
10.1038/sj.bjp.0702708. [PMID: 10455314] - A S Chong, W Huang, W Liu, J Luo, J Shen, W Xu, L Ma, L Blinder, F Xiao, X Xu, C Clardy, P Foster, J A Williams. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression.
Transplantation.
1999 Jul; 68(1):100-9. doi:
10.1097/00007890-199907150-00020. [PMID: 10428276] - Y Mizushima, Y Amano, H Kitagawa, K Ogata. Oral administration of leflunomide (HWA486) results in prominent suppression of immunoglobulin E formation in a rat type 1 allergy model.
The Journal of pharmacology and experimental therapeutics.
1999 Feb; 288(2):849-57. doi:
. [PMID: 9918599] - L C Hamilton, T D Warner. Interactions between inducible isoforms of nitric oxide synthase and cyclo-oxygenase in vivo: investigations using the selective inhibitors, 1400W and celecoxib.
British journal of pharmacology.
1998 Sep; 125(2):335-40. doi:
10.1038/sj.bjp.0702077. [PMID: 9786506] - X Xu, L Blinder, J Shen, H Gong, A Finnegan, J W Williams, A S Chong. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice.
Journal of immunology (Baltimore, Md. : 1950).
1997 Jul; 159(1):167-74. doi:
. [PMID: 9200452] - H T Silva Júnior, R E Morris. Leflunomide and malononitrilamides.
The American journal of the medical sciences.
1997 May; 313(5):289-301. doi:
10.1097/00000441-199705000-00008. [PMID: 9145039] - J Lucien, V C Dias, D F LeGatt, R W Yatscoff. Blood distribution and single-dose pharmacokinetics of leflunomide.
Therapeutic drug monitoring.
1995 Oct; 17(5):454-9. doi:
10.1097/00007691-199510000-00004. [PMID: 8585107] - V C Dias, J Lucien, D F LeGatt, R W Yatscoff. Measurement of the active leflunomide metabolite (A77 1726) by reverse-phase high-performance liquid chromatography.
Therapeutic drug monitoring.
1995 Feb; 17(1):84-8. doi:
10.1097/00007691-199502000-00014. [PMID: 7725383] - J W Patterson, P S Cheung, M J Ernest. 3-Carboxy-5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide, a new prodrug for the antiarthritic agent 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide.
Journal of medicinal chemistry.
1992 Feb; 35(3):507-10. doi:
10.1021/jm00081a011. [PMID: 1738142]
